Enjoy complimentary customisation on priority with our Enterprise License!
The Global Induced Pluripotent Stem Cells Production (iPSCs) Market size is forecast to increase by USD 1.84 billion, at a CAGR of 11.66% between 2023 and 2028.
There has been an increasing adoption of iPSCs in drug discovery and toxicity screening applications. In addition, traditional drug discovery methods often rely on animal models or immortalized cell lines, which may not accurately represent human physiology or predict drug responses in human beings. Moreover, iPSCs offer a more physiologically relevant alternative by allowing researchers to generate human cell-based models that closely resemble the cell types affected by diseases or targeted by drugs. Furthermore, researchers are increasingly turning to iPSC-derived cell models to screen potential drug candidates for efficacy and safety. Hence, such factors are positively impacting the market.
To learn more about this report, Download Report Sample
The Market is segmented into two key processes: Manual iPSC production and Automated iPSC production. Manual production involves labor-intensive techniques, while automation streamlines and scales the process. Innovations like the Mantarray platform are advancing automated production, optimizing the generation of iPSCs from various cell sources such as hepatocytes, fibroblasts, and keratinocytes. In drug discovery and development focused on cancer and oncology, iPSCs are invaluable tools. They enable the development of stem cell-based therapies using Embryonic stem cells and other sources, driving progress in regenerative medicine and cell therapy. Automated platforms offer consistency and reliability, supported by specialized consumables and kits for iPSC culture and manipulation.
The hospitals segment is estimated to witness significant growth during the forecast period. The hospitals segment represent a key end-user segment in the global iPSCs production market, as they leverage iPSC technology for different applications in regenerative medicine, disease modeling, and personalized healthcare. In addition, hospitals utilize iPSCs and iPSC-derived cell therapies to advance research and clinical initiatives that are aimed at developing innovative treatments for a wide range of diseases and conditions, including cardiovascular disorders, neurological diseases, and genetic disorders.
Get a glance at the market contribution of various segments Download PDF Sample
The hospitals segment was the largest segment and valued at USD 786.92 million in 2018. Moreover, iPSC-based therapies offer the potential to revolutionize patient care by providing personalized treatment options that are tailored to individual genetic profiles and disease characteristics. In addition, hospitals play a crucial role in the clinical translation of iPSC-based therapies by conducting clinical trials and offering cutting-edge treatments to patients in need, thereby driving the adoption of iPSCs, which, in turn, will spur the growth of the hospitals segment of the global iPSCs production market during the forecast period.
The consumables and kits segment plays a significant role in the global iPSCs production market, offering essential reagents, media, and tools for iPSC generation, culture maintenance, and differentiation. In addition, this segment encompasses a wide range of products that are tailored to meet the diverse needs of iPSC researchers and production facilities, including cell culture media, growth factors, cytokines, cell reprogramming kits, and gene editing tools. Moreover, companies offer consumables and kits for iPSC production, which contributes to the growth of the market in focus by supplying researchers and biotechnology companies with high-quality, standardized products that support efficient and reliable iPSC generation and maintenance. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.
The instrument product segment is an essential component of the global iPSCs production market, offering researchers and production facilities with specialized equipment and instrumentation for iPSC generation, culture maintenance, and characterization. In addition, this segment encompasses a diverse range of instruments, including cell reprogramming platforms, cell culture incubators, microscopes, flow meters, and automated cell processing systems, among others. Moreover, companies offer instruments for iPSC production, which contributes to the growth of the market by providing researchers and biotechnology companies with innovative tools that enhance workflow efficiency, reproducibility, and scalability in iPSC research and production. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The market in North America has the highest revenue due to the presence of key companies including Fate Therapeutics Inc. and Applied StemCell. In addition, these companies continually support biopharmaceutical companies through a diversified portfolio of analytical testing services covering aspects of drug discovery, development, and manufacturing. For instance, according to the CDC, more than half a million people die every year due to cancer, and approximately 610,000 people die of heart disease in the US. Moreover, the US and Canada will be the largest revenue contributing countries in the region as stable economies and strong infrastructural support the launch of new drugs or biopharmaceuticals. Furthermore, high investments in research and development (R and D) are further increasing the demand for high-quality iPSCs in these countries. Hence, such factors are driving the market in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Allele Biotechnology and Pharmaceuticals Inc: The company offers induced pluripotent stem cells production such as ready-to-use iPS cell lines which can be used for disease differention models.
ALSTEM, Applied Biological Materials Inc., Applied StemCell, ATCC, Axol Biosciences Ltd., Becton Dickinson and Co., Bio Techne Corp., Board of Regents of the University of Wisconsin System, Creative Biolabs, Cyagen Biosciences, Cynata Therapeutics Ltd., Evotec SE, Fate Therapeutics Inc., FUJIFILM Corp., Hitachi Ltd., LIFE and BRAIN GmbH, Lonza Group Ltd., Ncardia Services B.V., REPROCELL Inc., Sartorius AG, STEMCELL Technologies Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is driven by the increasing focus on drug discovery and development for cancer and regenerative medicine applications. Stem cell-based therapies utilizing Embryonic stem cells and automated platforms are trending, along with the demand for specialized consumables and kits. Challenges include addressing toxicology studies and ensuring clinical grade autologous iPSC therapies meet safety standards. Innovations like the Mantarray platform drive efficiency, while collaborations with companies like Fate Therapeutics shape future trends in iPSC production. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
Rising prevalence of several chronic disorders is notably driving the market. Chronic diseases including cardiovascular disorders, neurodegenerative conditions, and diabetes pose significant healthcare challenges worldwide, driving the demand for innovative therapeutic approaches. In addition, iPSCs offer a promising avenue for disease modeling, drug discovery, and cell-based therapies, as they enable researchers to generate patient-specific cell models and develop personalized treatments tailored to individual disease profiles.
Moreover, the four major chronic diseases prevalent worldwide are cardiovascular diseases (CVDs), cancer, chronic obstructive pulmonary disease, and type 2 diabetes, which mostly occur due to high blood pressure, high cholesterol levels, overweight, physical inactivity, unhealthy diet, and the use of tobacco. In addition, chronic diseases such as asthma, heart disease, cancer, and diabetes are usually incurable illnesses or conditions. Furthermore, these diseases can be prevented through exercise, improved diet, and early detection. Hence, such factors are driving the market during the forecast period.
Advancements in cell reprogramming techniques is a primary trend in the market. Cell reprogramming techniques facilitate the conversion of adult cells, such as skin or blood cells, into iPSCs, which possess the unique ability to become different cell types in the body. In addition, these advancements have led to more efficient and reliable methods for generating iPSCs, accelerating their adoption in research and therapeutic applications.
Moreover, several companies have contributed significantly to the development and commercialization of innovative cell reprogramming technologies. For instance, Cellular Dynamics International (CDI), a subsidiary of FUJIFILM Corp., specializes in the production of human iPSC-derived cells and tissues for drug discovery, toxicity testing, and regenerative medicine applications. Furthermore, CDIs proprietary MyCell platform enables the creation of iPSCs from diverse tissue sources and facilitates the scalable production of differentiated cell types for research and clinical use. Hence, such factors are driving the market during the forecast period.
High costs associated with reprogramming of cells is a major challenge hindering the market. Reprogramming adult cells into iPSCs comprises complex and labor-intensive procedures, including the delivery of reprogramming factors, cell culture maintenance, and quality control assessments. In addition, these processes require specialized equipment, reagents, and expertise, driving up the overall cost of iPSC production.
Moreover, the need for rigorous quality control measures to ensure the genetic stability and safety of iPSC-derived cells further adds to the cost burden. As a result, researchers, academic institutions, and biotechnology companies face substantial financial barriers in establishing and maintaining iPSC production facilities and conducting large-scale reprogramming projects. Hence, such factors are driving the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The Market is at the forefront of drug discovery and development in oncology and other areas like disease intervention. Stem cell-based therapies, particularly those involving Embryonic stem cells and clinical grade autologous iPSC therapies, are revolutionizing treatment modalities. With advancements in cell therapy, both manual and automated iPSC production processes are being utilized, with automated platforms offering higher efficiency and scalability.
Moreover, toxicology studies play a crucial role in ensuring the safety and efficacy of these therapies. Research and academic institutes, alongside contract research organizations, are driving innovations in biotechnology research and development within the life sciences sector. Salivary glands and Human Induced Salivary Glands are also areas of interest for regenerative medicine. CAR-T cell treatment and platforms like Mantarray are expanding possibilities for personalized medicines targeting monogenic and polygenic disorders, including psychiatric diseases. Biomarkers are key in tracking progress, especially in clinical studies and research collaboration.
Furthermore, the process involves reprogramming somatic cells through reprogramming methods such as retroviruses or chemical reprogramming, although issues like genetic instability and chromosomal instability require careful cell characterization and engineering. This market is also exploring applications in tissue engineering for wound healing and addressing vascular health complications in ischemic tissues and blood vessels. Government funding and initiatives from stem cell research centers are pivotal in advancing Stem Cell Therapies Mission and technologies like Cell Squeeze for enhancing Dopaminergic neurons in conditions like Parkinson's disease. However, ethical concerns remain significant in navigating this frontier of genetic reprogramming and pluripotency.
Market Scope |
|
Report Coverage |
Details |
Page number |
169 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 11.66% |
Market growth 2024-2028 |
USD 1.84 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
10.09 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 34% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Allele Biotechnology and Pharmaceuticals Inc., ALSTEM, Applied Biological Materials Inc., Applied StemCell, ATCC, Axol Biosciences Ltd., Becton Dickinson and Co., Bio Techne Corp., Board of Regents of the University of Wisconsin System, Creative Biolabs, Cyagen Biosciences, Cynata Therapeutics Ltd., Evotec SE, Fate Therapeutics Inc., FUJIFILM Corp., Hitachi Ltd., LIFE and BRAIN GmbH, Lonza Group Ltd., Ncardia Services B.V., REPROCELL Inc., Sartorius AG, STEMCELL Technologies Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.